Ginsenoside CK

Ginsenoside CK is a metabolite of the saponin ginsenoside Rb1 (Cay-15319) that has diverse biological activities. Ginsenoside CK is formed from ginsenoside Rb1 via intestinal bacterial exo-beta-D-glucosidase. It reduces protein levels of matrix metalloproteinase-2 (MMP-2) and pro-MMP-9 in, and inhibits growth, adhesion, and invasion of, MHCC97-H human hepatocellular carcinoma cells (HCCs) when used at concentrations of 50 and 75 µM. It inhibits metastasis in an MHCC97-H mouse xenograft model but does not reduce tumor growth. Ginsenoside CK reduces the percentage of memory B cells in the spleen, the number of swollen joints, and lymph node hyperplasia in an adjuvant-induced model of rheumatoid arthritis. It increases the activity of pSer9-glycogen synthase kinase and insulin degrading enzyme (IDE) and reduces the accumulation of amyloid-beta (1-42) (Abeta42, Cay-20574) in the rat hippocampal CA1 and CA3 regions in a model of vascular dementia induced by chronic cerebral hypofusion. It also increases the percentage of time spent in the target quadrant of the Morris water maze when administered at doses of 100 and 200 mg/kg in the same model.Formal Name: (3beta,12beta)-3,12-dihydroxydammar-24-en-20-yl, beta-D-glucopyranoside. CAS Number: 39262-14-1. Synonyms: Ginsenoside Compound K, Ginsenoside IH901. Molecular Formula: C36H62O8. Formula Weight: 622.9. Purity: >95%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 10 mg/ml, DMSO: 10 mg/ml, DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml. SMILES: O[C@H]1[C@@]2([H])[C@](CC[C@]2([H])[C@@](CC/C=C(C)/C)(C)O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)(C)[C@]4(C)CC[C@]5([H])[C@@](CC[C@H](O)C5(C)C)(C)[C@@]4([H])C1. InChi Code: InChI=1S/C36H62O8/c1-20(2)10-9-14-36(8,44-31-30(42)29(41)28(40)23(19-37)43-31)21-11-16-35(7)27(21)22(38)18-25-33(5)15-13-26(39)32(3,4)24(33)12-17-34(25,35)6/h10,21-31,37-42H,9,11-19H2,1-8H3/t21-,22+,23+,24-,25+,26-,27-,28+,29-,30+,31-,33-,34+,35+,36-/m0/s1. InChi Key: FVIZARNDLVOMSU-IRFFNABBSA-N.